Skip to main content

Table 4 Stratified analysis adjusted mortality

From: Association between β-blocker use and mortality in critically ill patients: a nested cohort study

  180 Day Mortality ICU Mortality Hospital Mortality
Variable N aOR 95% CI P value
for interaction
N aOR 95% CI P value
for interaction
N aOR 95% CI P value
for interaction
Age (years)
Age < 58 230 0.57 0.10–3.2 0.58 263 1.89 0.56–6.4 0.43 263 1.21 0.41–3.5 0.27
Age >  58 247 0.83 0.43–1.62 260 1.48 0.72–3.1 260 1.11 0.62–1.99
Gender
Male 355 0.54 0.23–1.26 0.57 391 1.72 0.80–3.68 0.14 391 0.95 0.49–1.85 0.82
Female 122 1.45 0.52–4.1 132 1.30 0.44–3.88 132 1.45 0.62–3.39
Diabetes
Yes 194 0.63 0.30–1.36 0.07 208 0.93 0.40–2.17 0.01 208 0.73 0.39–1.38 0.002
No 283 1.22 0.40–3.7 315 2.93 1.19–7.23 315 2.43 1.05–5.64
Vasopressors
Yes 307 0.70 0.32–1.50 0.36 341 1.86 0.89–3.89 0.85 341 1.25 0.67–2.32 0.84
No 170 1.10 0.32–3.74 182 0.89 0.27–2.99 182 0.83 0.32–2.18
APACHE II score
<  23 236 0.85 0.22–3.26 0.32 271 2.22 0.66–7.48 0.12 271 1.12 0.40–3.13 0.23
>  23 241 0.67 0.32–1.40 252 1.23 0.59–2.56 252 0.98 0.53–1.82
Sepsis
Yes 117 0.83 0.24–2.95 0.37 122 1.06 0.30–3.78 0.12 122 0.92 0.32–2.63 0.06
No 360 0.71 0.33–1.51 401 1.91 0.90–4.08 401 1.26 0.70–2.37
Severe sepsis
Yes 115 0.52 0.11–2.41 0.71 125 0.73 0.25–2.09 0.19 125 0.71 0.25–2.01 0.72
No 362 0.80 0.39–1.62 398 2.09 092–4.73 398 1.10 0.59–2.06
Admission category
Non-operative 404 0.79 0.41–1.52 0.92 435 1.50 0.78–2.90 0.50 435 1.15 0.67–1.98 0.81
Post-operative 73 0.21 0.015–3.0 88 1.96 0.26–14.71 88 0.52 0.09–3.06
Chronic Respiratory Disease
Yes 68 1.15 0.21–6.32 0.85 70 4.89 1.18–20.30 0.11 70 7.27 1.39–37.93 0.06
No 409 0.62 0.30, 1.26 453 1.28 0.61–2.71 453 0.80 0.44–1.43
Chronic Renal disease
Yes 53 1.22 0.33–4.5 0.97 55 1.39 0.29–6.63 0.69 55 0.82 0.24–2.77 0.25
No 424 0.60 0.28–1.27 468 1.55 0.78–3.09 468 1.10 0.62–1.96
Chronic Cardiac disease
Yes 74 0.56 0.18–1.71 0.13 77 0.69 0.19–2.48 0.09 77 0.45 0.16–1.29 0.003
No 403 0.75 0.34–1.64 446 1.88 0.92–3.85 446 1.34 0.74–2.44
Estimated GFR (mL/min)
≤ 73 246 0.82 0.42–1.62 0.23 261 1.02 0.50–2.05 0.08 261 0.84 0.47–1.50 0.06
> 73 231 0.21 0.03–1.54 262 3.40 0.89–12.89 262 1.36 0.44–4.25
SOFA score
≤ 9 274 0.70 0.26–1.84 0.56 305 1.39 0.51–3.79 0.99 305 0.89 0.40–1.97 0.90
>  9 203 0.77 0.31–1.85 218 1.62 0.71–3.68 218 1.29 0.61–2.73
ICU duration (days)
≤ 5 231 0.74 0.28–1.92 0.70 256 1.44 0.52–4.03 0.51 256 1.07 0.46–2.47 0.31
>  5 246 0.70 0.29–1.71 267 1.60 0.71–3.58 267 1.06 0.50–2.25
Statin Use
Yes 66 0.92 0.30–2.79 0.86 68 0.46 0.10–2.10 0.02 68 1.005 0.35–2.92 0.19
No 411 0.65 0.28–1.51 455 2.29 1.16–4.54 455 1.40 0.76–2.57
  1. aOR adjusted odds ratio, APACHE Acute Physiology and Chronic Health Evaluation, CI confidence interval, GFR glomerular filtration rate, ICU intensive care unit, SOFA Sequential Organ Failure Assessment